Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 16/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 3/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.34 |
| ▸ | KDR | P35968 | 2/20 | 0.34 |
| ▸ | FLT3 | P36888 | 2/20 | 0.34 |
| ▸ | FLT4 | P35916 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1722207 | 0.87 | GCK (0.69) | GCK | |
| SCHEMBL1724126 | 0.86 | GCK (0.73) | GCKKDM4EPOLBHTTTDP1 | |
| SCHEMBL1725087 | 0.83 | GCK (0.56) | GCKKDM4EPOLBHTTTDP1 | |
| SCHEMBL1723144 | 0.78 | KDM4E (0.47) | GCKKDM4EPOLBHTTTDP1 | |
| SCHEMBL1725331 | 0.76 | GCK (0.68) | GCKKDM4EPOLBHTTTDP1 | |
| SCHEMBL1724658 | 0.76 | GCK (0.58) | GCKKDM4EPOLBHTTTDP1 | |
| SCHEMBL1721932 | 0.75 | GCK (0.75) | GCKKDM4EPOLBHTTTDP1 | |
| SCHEMBL1727457 | 0.74 | GCK (0.55) | GCK | |
| SCHEMBL1722832 | 0.73 | KDM4E (0.49) | GCKKDM4EPOLBHTTTDP1 | |
| SCHEMBL1724929 | 0.73 | GCK (0.72) | GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2406230-A1 | SUBSTITUTED INDAZOLE AMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | Pfizer Inc. (US) | 2012-01-18 | — | — | EP | disclosed |
| US-20110319379-A1 | Substituted Indazole Amides And Their Use As Glucokinase Activators | CORBETT JEFFREY W (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319379-A1 | Substituted Indazole Amides And Their Use As Glucokinase Activators | CORBETT JEFFREY W (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319379-A1 | Substituted Indazole Amides And Their Use As Glucokinase Activators | CORBETT JEFFREY W (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2010103438-A1 | SUBSTITUTED INDAZOLE AMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | PFIZER INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010103438-A1 | SUBSTITUTED INDAZOLE AMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | PFIZER INC. (US) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319379-A1 | Substituted Indazole Amides And Their Use As Glucokinase Activators | GCKR, GCK, GALK1 | GCK 2/4885KDM4E 1622/4885POLB 4318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.